Table 3 Standardized change from baseline in FEV1 AUC0–12 on Day 7 (pooled population)
Parameter | Placebo | Glycopyrrolate | Aclidinium | |||||
|---|---|---|---|---|---|---|---|---|
(n = 149) | 3 μg BID (n = 91) | 6.25 μg BID (n = 92) | 12.5 μg BID (n = 145) | 25 μg BID (n = 54) | 50 μg BID (n = 149) | 100 μg BID (n = 59) | 400 μg BID (n = 94) | |
Baseline FEV1 | ||||||||
n | 149 | 91 | 92 | 144 | 54 | 149 | 59 | 94 |
Mean (SD), L | 1.296 (0.429) | 1.363 (0.429) | 1.380 (0.440) | 1.302 (0.421) | 1.205 (0.425) | 1.321 (0.433) | 1.202 (0.463) | 1.395 (0.464) |
Standardized change from baseline in FEV1 AUC0–12 on Day 7 | ||||||||
n | 146 | 91 | 92 | 143 | 53 | 146 | 59 | 90 |
Mean (SD), L | −0.016 (0.187) | 0.034 (0.178) | 0.068 (0.181) | 0.130 (0.174) | 0.167 (0.200) | 0.163 (0.201) | 0.210 (0.143) | 0.153 (0.224) |
LS mean (SE), L | −0.016 (0.016) | 0.036 (0.020) | 0.071 (0.020) | 0.129 (0.016) | 0.162 (0.026) | 0.163 (0.016) | 0.205 (0.025) | 0.156 (0.020) |
95% CI | −0.047, 0.014 | −0.003, 0.074 | 0.032, 0.109 | 0.098, 0.160 | 0.112, 0.213 | 0.133, 0.194 | 0.157, 0.253 | 0.117, 0.195 |
Placebo-adjusted change from baseline in FEV1 AUC0–12 on Day 7 | ||||||||
LS mean (SE), L | – | 0.052 (0.025) | 0.087 (0.025) | 0.145 (0.022) | 0.178 (0.030) | 0.180 (0.022) | 0.221 (0.029) | 0.172 (0.025) |
95% CI | – | 0.003, 0.101 | 0.038, 0.136 | 0.102, 0.188 | 0.120, 0.237 | 0.137, 0.223 | 0.164, 0.278 | 0.123, 0.221 |